Ai-Biopharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ai-Biopharma is a Paris-based, AI-driven drug discovery company operating a dual business model of providing computational chemistry services and developing its own therapeutic assets. Founded by seasoned pharmaceutical industry veterans, the company combines deep medicinal chemistry expertise in antiviral and nucleoside chemistry with a proprietary AI platform for drug design and optimization. Its primary focus is on accelerating the identification and optimization of preclinical candidates, with internal programs targeting viral diseases. The company appears to be a privately held, preclinical-stage entity.

Viral DiseasesHepatitis B

Technology Platform

Integrated AI platform for drug design acceleration, encompassing chemoinformatics, molecular modeling, docking, data analysis, and SAR interpretation to enable faster design and optimization of preclinical candidate drugs.

Opportunities

The growing demand for AI-driven drug discovery services provides a near-term revenue path.

Successfully developing a novel therapy for Hepatitis B, a large market with significant unmet need, represents a major long-term value creation opportunity.

Validating the internal AI platform could also lead to lucrative platform licensing or broad collaboration deals.

Risk Factors

The company faces high scientific risk that its AI platform can reliably produce successful clinical candidates, and its lead program is at an early preclinical stage with inherent attrition risk.

As a private, early-stage company, it is dependent on securing external funding in a competitive investment landscape.

Competitive Landscape

Ai-Biopharma competes in the crowded AI-drug discovery sector against other AI-native biotechs (e.g., Exscientia, Recursion, Insilico Medicine) and large pharma internal efforts. Its differentiation lies in its deep, proven expertise in antiviral/nucleoside medicinal chemistry, providing a focused niche compared to more generalist AI platforms.

More companies in AI / Machine Learning →More companies in France →